Clinical pharmacology of old age syndromes

British Journal of Clinical Pharmacology

Volumn 56, Issue 3, 2003, Pages 261-272

  Broadhurst, C ^a,e   Wilson, K C M ^a   Kinirons, M T ^b   Wagg, A ^c   Dhesi, J K ^d  

^a St Catherine's Hospital   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c ST PANCRAS HOSPITAL   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e St Catherine's Hospital   (United Kingdom)

Author keywords

Delirium; Elderly; Nonpharmacological; Pathophysiology; Pharmacological; Treatment

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CALCITONIN GENE RELATED PEPTIDE; CHOLECYSTOKININ; CHOLINESTERASE INHIBITOR; CLOMETHIAZOLE; DIAZEPAM; DONEPEZIL; DROPERIDOL; ENKEPHALIN DERIVATIVE; FLUNITRAZEPAM; HALOPERIDOL; IMIPRAMINE; LORAZEPAM; MIANSERIN; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; OXYBUTYNIN; PROPIVERINE; PROSTANOID RECEPTOR; PURINE RECEPTOR; RISPERIDONE; SUBSTANCE P; TACHYKININ RECEPTOR; TETRACYCLIC ANTIDEPRESSANT AGENT; TOLTERODINE; TROSPIUM CHLORIDE; UNINDEXED DRUG; VANILLOID RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE;

AGED; AGING; ANTICHOLINERGIC EFFECT; CARDIOTOXICITY; CLINICAL PHARMACOLOGY; CLINICAL RESEARCH; CONSTIPATION; DELIRIUM; DETRUSOR DYSSYNERGIA; FALLING; GASTROESOPHAGEAL REFLUX; HEART VENTRICLE ARRHYTHMIA; HUMAN; LONG QT SYNDROME; MORTALITY; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOCIAL SUPPORT; SYNDROME DELINEATION; URINE INCONTINENCE; VISUAL IMPAIRMENT; VITAMIN SUPPLEMENTATION; XEROSTOMIA;

ACCIDENTAL FALLS; AGED; DELIRIUM; DIETARY SUPPLEMENTS; EXERCISE TOLERANCE; FRACTURES, BONE; HUMANS; MUSCULAR DISEASES; POSTURE; SYNDROME; URINARY INCONTINENCE; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 0041317454     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0306-5251.2003.01877.x     Document Type: Review

References (169)

1. Gillick MR, Serrell NA, Gillick LS. Adverse consequences of hospitalization in the elderly. Soc Sci Med 1982; 16: 1033-1038.
2. Francis J, Martin D, Kapoor WN. A prospective study of delirium in hospitalized elderly. JAMA 1990; 263: 1097-1101.
3. Forman LJ, Cavalieri TA, Galski T, Dinsmore S, Kay PA, Pomerantz S. Occurrence and impact of suspected delirium in hospitalized elderly patients. J Am Osteopath Assoc 1995; 10: 588-591.
4. O'Keefe S, Lavan J. The prognostic significance of delirium in older hospitalised patients. J Am Geriatr Soc 1997; 45: 247-248.
5. Solomon S, Madeu JC. Neurological evaluation. In Comprehensive textbook of psychiatry, 4th edn. Baltimore: Wilkins & Wilkins, 1989; 144-176.
6. Itil T, Fink M. Anticholinergic drug induced delirium: experimental modification, quantitative EEG and behavioural correlations. J New Ment Dis 1966; 143: 492-507
7. Granacher RP, Baldessarini RJ. Physostigmine. Its use in acute anticholinergic syndrome with antidepressant and antiparkinsonian drugs. Arch General Psychiatry 1975; 32: 375-380.
8. Flacker JM, Cummings V, Mach JR Jr, Bettin K, Kiely DK, Wei J. The association of serum anticholinergic activity with delirium in elderly medical patients. Am J Geriatr Psychiatry 1998; 6: 31-41.
9. Flacker JM, Lipsitz LA. Neural mechanisms of delirium: current hypotheses and evolving concepts. J Gerontol A Biol Sci Med Sci 1999; 54: B239-B246.
10. van der Mast RC. Pathophysiology of delirium. J Geriatr Psychiatry Neurol 1998; 11: 138-145.
11. American Psychiatric Association. Practice guideline for the treatment of patients with delirium. Washington DC: APA, 1999; 156 5(Suppl): 1-20.
12. Tune L. The role of antipsychotics in treating delirium. Curr Psychiatry Rep 2002; 4: 209-212.
13. Schroder-Rosenstock K, Busch H. Pharmacopsychiatric guidelines for treatment of alcohol withdrawal syndrome. Z Arztl Fortbild (Jena) 1996; 90: 301-306.
14. Hawley RJ, Major LF, Schulman EA, Lake CR. CSF levels of norepinephrine during alcohol withdrawal. Arch Neurol 1981; 38: 289-292
15. Bergqvist PB, Some M, Apelqvist G, Helander A, Bengtsson F. Elevated brain 5-hydroxytryptophol levels in experimental portal-systemic encephalopathy. Pharmacol Toxicol 1997; 80: 187-190.
16. Banki CM, Vojnik M. Comparative simultaneous measurement of CSF 5-hydroxyindoleacetic acid and blood serotonin levels in delirium tremens and clozapine-induced delirious reaction. J Neurol Neurosurg Psychiatry 1978; 41: 420-424.
17. Koponen HJ, Lepola U, Leinonen E. A long-term follow up study of cerebrospinal fluid 5-hydroxyindoleacetic acid in delirium. Eur Arch Psychiatry Clin Neurosci 1994; 244: 131-134.
18. van der Mast RC, Fekkes D, Moleman P, Pepplinkhuizen L. Is postoperative delirium related to reduced plasma tryptophan? Lancet 1991; 338: 851-852.
19. Leinonen E, Koponen H, Lepola U. Delirium during fluoxetine treatment. A case report. Ann Clin Psychiatry 1993; 5: 255-257.
20. Nakamura J, Uchimura N, Yamada S, Nakazawa Y. Effects of mianserin hydrochloride on delirium: comparison with the effects of oxypertine and haloperidol. Yakubutsu Seishin Kodo 1994; 14: 269-277.
21. Mayo-Smith MF. Pharmacological management of alcohol withdrawal: a meta analysis and evidence-based practice guideline. JAMA 1997; 278: 144-151.
22. Bostwick JM, Masterson BJ. Psychopharmacological treatment of delirium to restore mental capacity. Psychosomatics 1998; 39: 112-117.
23. Baraldi M, Zeneroli ML. Experimental hepatic encephalopathy. Changes in the binding of GABA. Science 1982; 216: 427-429.
24. Jones EA, Skolnick P, Gammal SH, Basile AS, Mullen KD. NIH conference. The gamma-aminobutyric acid A (GABAA) receptor complex and hepatic encephalopathy. Some recent advances. Ann Intern Med 1989; 110: 532-546.
25. Tsai G, Coyle JT. The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Ann Rev Med 1998; 49: 173-184.
26. Jones EA. Pathogenesis of hepatic encephalopathy. Clin Liver Dis 2000; 4: 467-485.
27. Koponen H, Riekkinen J. A longitudinal study of cerebrospinal fluid beta-endorphin-like immunoreactivity in delirium: changes at acute stage and one year follow up. Acta Psychiatr Scand 1990; 82: 323-326.
28. Kaponen HJ, Leinonen E, Lepola U, Riekkinen PJ. A long-term follow-up study of cerebrospinal fluid somatostatin in delirium. Acta Psychiatr Scand 1994; 89: 329-334.
29. Rosenberg S, Loetz M, Yang J. Experience with the use of high dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474-484.
30. Denicoff K, Rubinow DR, Papa MZ et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphocyte activated killer cells. Ann Intern Med 1987; 107: 293-300.
31. O'Keefe ST, Devlin JG. Delirium and the dexamethasone suppression test in the elderly. Neuropsychobiology 1994; 30: 153-156.
32. Britton A, Russell R. Multidisciplinary team interventions for delirium in patients with chronic cognitive impairment. Cochrane Database Syst Rev 2001; 1: CD000395.
33. Harwood DM, Hope T, Jacoby R. Cognitive impairment in medical inpatients. 1. Screening for dementia - is history better than mental state? Age Ageing 1997; 26: 31-35.
34. Meagher DJ. Delirium: optimising management. Br Med J 2001; 322: 144-149.
35. Schofield I. A small exploratory study of the reaction of older people to an episode of delirium. J Adv Nurs 1997; 25: 942-952.
36. Meagher DS, O'Hanlon D, O'Mahony E, Casey PR. The use of environmental strategies and psychotropic medication in the management of delirium. Br J Psychiatry 1996; 168: 512-515.
37. Simon L, Jewell N, Brokel J. Management of acute delirium in hospitalized elderly: a process improvement project. Geriatr Nuts 1997; 18: 150-154.
38. Ryan C, Tahet N, Howard R et al. Optimising management of delirium. Br Med J 2001; 322: 1602.
39. Tabet N, Howard R. Patients with delirium should be treated with care. Br Med J 2001; 322: 1602.
40. Breitbart W, Marotta R, Platt MM et al. A double blind trial of haloperidol, chlorpromazine and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996; 153: 231-237.
41. Resnick M, Burton BT. Droperidol vs. haloperidol in the initial management of acutely agitated patients. J Clin Psychiatry 1984; 45: 298-299.
42. Thomas H Jr, Schwartz E, Petrilli R. Droperidol versus haloperidol for chemical restraint of agitated and combative patient. Ann Emerg Med 1992; 21: 407-413.
43. Haines J, Barclay P, Wauchob T. Optimising management of delirium. Withdrawal of Droleptan (droperidol). Br Med J 2001; 322: 1603.
44. Rosen H. Double blind comparison of haloperidol and thioridazine in geriatric patients. J Clin Pharmacol 1979; 40: 17-20.
45. Brown RL, Henke A, Greenhalgh DG, Warden GD. The use of haloperidol in the agitated, critically ill pediatric patient with burns. J Burn Care Rehabil 1996; 17: 34-38.
46. Di Salvo TG, O'Gara PT. Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients. Clin Cardiol 1995; 18: 285-290.
47. Perrault LP, Denault AY, Carrier M, Cartier R, Belisle S. Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery. Can J Anaesth 2000; 47: 251-254.
48. Fish DN. Treatment of delirium in the critically ill patient. Clin Pharm 1991; 10: 456-466.
49. Schwartz TL, Masand PS. The role of atypical antipsychotics in the treatment of delirium. Psychosomatics 2002; 43: 171-174.
50. Ravona-Springer R, Dolberg OT, Hirschmann S, Grunhaus L. Delirium in elderly patients treated with risperidone: a report of three cases. J Clin Psychopharmacol 1998; 18: 171-172.
51. Sipahimalani A, Masand PS. Use of risperidone in delirium: case reports. Ann Clin Psychiatry 1997; 9: 105-107.
52. Furmaga KM, DeLeon OA, Sinha SB, Jobe TH, Gaviria M. Psychosis in medical conditions: response to risperidone. General Hosp Psychiatry 1997; 19: 223-228.
53. Sipahimalani A, Masand PS. Olanzapine in the treatment of delirium. Psychosomatics 1998; 39: 422-430.
54. Kim KS, Pae CU, Chae JH, Bahk WM, Jun T. An open pilot trial of olanzapine for delirium in the Korean population. Psychiatry Clin Neurosci 2001; 55: 515-519.
55. Passik SD, Cooper M. Complicated delirium in a cancer patient successfully treated with olanzapine. J Pain Symptom Manage 1999; 17: 219-223.
56. Breitbart W, Tremblay A, Gibson C. An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics 2002; 43: 175-182.
57. Schwartz TL, Masand PS. Treatment of delirium with quetiapine. J Clin Psychiatry 2000; 2: 10-12.
58. Menza MA, Murray GB, Holmes VF, Rafuls WA. Controlled study of extrapyramidal reactions in the management of delirious medically ill patients, intravenous haloperidol versus intravenous haloperidol plus benzodiazepines. Heart Lung 1988; 7: 238-241.
59. Shigeta M, Homma A. Donepezil for Alzheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles. CNS Drug Rev 2001; 7: 353-368.
60. Wengel SP, Roccaforte WH, Burke WJ. Donepezil improves symptoms of delirium: implications for future research. J Geriatr Psychiatry Neurol 1998; 11: 159-161.
61. Diaz V, Rodriguez J, Barrientos P. Use of procholinergics in the prevention of postoperative delirium in hip fracture surgery in the elderly. A randomized controlled trial. Rev Neurol 2001; 33: 716-719.
62. Aizawa K, Kanai T, Saikawa Y et al. A novel approach to the prevention of postoperative delirium in the elderly after gastrointestinal surgery. Surg Today 2002; 32: 310-304.
63. Sumner AD, Simons RJ. Delirium in the hospitalized elderly. Cleve Clin J Med 1994; 61: 258-262.
64. Zilker T. Alcohol withdrawal syndrome and delirium tremens. Diagnosis and therapy. MMW Fortschr Med 1999; 141: 26-30.
65. Croissant B, Mann K. Alcohol withdrawal syndrome and its treatment. Ther Umsch 2000; 57: 257-260.
66. Ulrich S, Danos P, Baumann B et al. Serum concentration of chlormethiazole and therapeutic effect in acute alcohol withdrawal syndrome: an open clinical trial. Ther Drug Monit 2002; 24: 446-454.
67. Franz M, Dlabal H, Kunz S, Ulferts J, Gruppe H, Gallhofer B. Treatment of alcohol withdrawal: tiapride and carbamazepine versus clomethiazole. A pilot study. Eur Arch Psychiatry Clin Neurosci 2001; 351: 185-192.
68. Thome J, Wiesbeck GA, Vince GH. Carbamazepine in treatment of alcohol withdrawal syndrome - an overview of current research. Fortschr Neurol Psychiatr 1994; 62: 125-133.
69. Taylor D, McConnell H, McConnell D, Kerwin R eds. The Maudsley 2001 prescribing guidelines, 6th edn. London: Martin Dunitz, 2001.
70. Daeppen JB, Gache P, Landry U. Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial. Arch Intern Med 2002; 162: 1093-1094.
71. Inouye SK. Prevention of delirium in hospitalized older patients: risk factors and targeted intervention strategies. Ann Med 2000; 4: 257-263.
72. Hatton J, Rapp RP, Kudsk KA et al. Intravenous insulin-like growth factor-I (IGF-I) in moderate-to-severe head injury: a phase II safety and efficacy trial. J Neurosurg 1997; 86: 779-786.
73. Taylor PC. Anti-tumor necrosis factor therapies. Curr Opin Rheumatol 2001; 13: 164-169.
74. Abramson SB, Amin A. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology (Oxford) 2002; 41: 972-980.
75. Broadhurst C, Wilson K. Immunology of delirium: new opportunities for treatment and research. Br J Psychiatry 2001; 179: 288-289.
76. Kronfrol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 2000; 157: 683-694.
77. Hassan E, Fontaine DK, Nearman HS. Therapeutic considerations in the management of agitated or delirious critically ill patients. Pharmacotherapy 1998; 18: 113-129.
78. Bayliss M, Wu C, Newgreen D, Mundy AR, Fry CH. A quantitative study of atropine-resistant contractile responses in human detrusor smooth muscle, from stable, unstable and obstructed bladders. J Urol 1999; 162: 1833-1839.
79. Brading AF, Turner WH. The unstable bladder: towards a common mechanism. Br J Urol 1994; 73: 3-8.
80. Gilpin SA, Gilpin CJ, Dixon JS, Gosling JA, Kirby RS. The effect of age on the autonomic innervation of the bladder. Br J Urol 1986; 58: 378-381.
81. De Groat WC. A neurological basis for the overactive bladder. Urology 1997; 50 (Suppl 6A): 36-52.
82. Brading AF. A myogenic basis for the overactive bladder. Urology 1997; 50 (Suppl 6A): 57-67.
83. Fry CH, Wu C. The cellular basis of bladder instability. Br J Urol 1998; 81: 1-8.
84. Abrams P. Bladder instability: concept, clinical associations and treatment. Scand J Urol Nelohrol 1984; 87: 7-12.
85. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-766.
86. Abrams PH, Cardozo L, Fall M et al. The standardization of terminology of lower urinary tract function: report from the Standardization Sub-committee of the International Continence Society. Neurol Urodyn 2002; 21: 167-168.
87. Cardozo LD, Stanton SL. An objective comparison of the effects of parenterally administered drug in patients suffering from detrusor instability. J Urol 1979; 122: 58-59.
88. Blaivas JG, Labib KB, Michalik J, Zayed AAH. Cystometric response to propantheline in detrusor hyperreflexia: therapeutic implications. J Urol 1980; 124: 259-262.
89. Zorzitto ML, Jewett MAS, Fernie GR, Holliday PJ, Bartlett S. Effectiveness of propantheline bromide in the treatment of geriatric patients with detrusor instability. Neurourol Urodyn 1986; 5: 133-140.
90. Jonas U, Hornet K, Madersbacher H, Holmdahl TH. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. World J Urol 1997; 15: 144-151.
91. Hashimoto K, Ohnishi N, Esa A, Sugiyama T, Park Y-C, Kurita T. Clinical efficacy of oxybutynin on sensory urgency as compared with motor urgency. Urologia Int 1999; 62: 12-16.
92. Cardozo LD, Cooper D, Versi E. Oxybutynin chloride in the management of idiopathic detrusor instability. Neurourol Urodyn 1987; 6: 256-257.
93. Moisey CU, Stephenson TP, Brendler CB. The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride. Br J Urol 1980; 52: 472-475.
94. Bemelmans BL, Kiemeney LA, Debruyne FM. Low-dose oxybutynin for the treatment of urge incontinence: good efficacy and few side effects. Eur Urol 2000; 37: 709-713.
95. Malone-Lee JG, Lubel D, Szonyi G. Low dose oxybutynin for the unstable bladder. Br Med J 1992; 304: 1053.
96. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 1997; 104: 988-993.
97. Ouslander JG, Schnelle JF, Uman G et al. Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo controlled trial. J Am Geriatr Soc 1995; 43: 610-617.
98. Birns J, Lukkari E, Malone-Lee JG. A randomized controlled trial comparing the efficacy of controlled release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. BJU Int 2000; 85: 793-799.
99. Versi E, Appell R, Mobley D, Patton W, Saltzstein D. Dry mouth with conventional and controlled release oxybutynin in urinary incontinence. Obstet Gynecol 2000; 95: 718-721.
100. Anderson R, Mobley D, Blank B, Saltzstein D, Susset J, Brown J. Once daily controlled versus immediate release oxybutynin for urge urinary incontinence. J Urol 1999; 161: 1809-1812.
101. Nilvebrandt L, Hallen B, Larsson G. Tolterodine - a new bladder selective antimuscarinic agent. Eur J Pharmacol 1997; 327: 195-207.
102. Nilvebrandt L, Gillberg PG, Sparf B. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine. Pharmacol Toxicol 1997; 81: 169-172.
103. Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998; 81: 801-810.
104. Millard R, Tuttle J, Moore K et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol 1999; 161: 1551-1555.
105. Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001; 49: 700-705.
106. Malone-Lee J, Shaffu B, Anand C, Powell C. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol 2001; 165: 1452-1456.
107. Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended release once daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 2002; 50: 799-807.
108. Appell RA, Abrams P, Drutz HP, Van Kerrebroeck PE, Millard R, Wein A. Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J Urol 2001; 19: 141-147.
109. Lawrence M, Guay DR, Benson SR, Anderson MJ. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy 2000; 20: 470-475.
110. Chancellor MB, Appell RA, Sathyan G, Gupta SK. A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate. Clin Ther 2001; 23: 753-760.
111. Appell RA, Sand P, Dmochowski R et al. Prospective randomized controlled trial of extended release oxybutinin chloride and tolterodine in the treatment of overactive bladder: results of the OBJECT trial. Mayo Clin Proc 2001; 76: 358-363.
112. Todorava A, Vonderheid-Guth B, Dimpfl W. Effects of tolterodine, oxybutinin and trospium chloride on the central nervous system. J Clin Pharmacol 2001; 41: 636-644.
113. Diokno AC, Hyndman CW, Hardy DA, Lapides J. Comparison of action of imipramine (Tofranil) and propantheline (Propanthine) on detrusor contraction. J Urol 1972; 107: 42-43.
114. Castleden CM, Duffin HM, Gulati RS. Double blind study of imipramine and placebo for incontinence due to bladder instability. Age Ageing 1986; 15: 299-303.
115. Lose G, Jorgensen L, Thunedborg P. Doxepin in the treatment of female detrusor overactivity: a randomised double blind cross over study. J Urol 1989; 142: 1024-1026.
116. Stohrer M, Madersbacher H, Richter R, Wehnert J, Dreikorn K. Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia - a double-blind, placebo-controlled clinical trial. Spinal Cord 1999; 37: 196-200.
117. Madersbacher H, Halaska M, Voigt R, Alloussi S, Hofner KA. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutinin in patients with urgency and urge incontinence. BJU Int 1999; 84: 646-651.
118. Halaska M, Dorschner W, Frank M. Treatment of urgency and incontinence in elderly patients with propiverine hydrochloride. Neurol Urodyn 1994; 13: 428-430.
119. Fuertes ME, Garcia Matres MJ, Gonzalez Romojaro V et al. Ensayo clinico para evaluar la eficacia y tolerancia del cloruro de trospio (Uraplex) en pacientes con incontinencia por inestabilidad del detrusor y su repercusion en la calidad de vida. Arch Esp Urol 2000; 53: 125-136.
120. Cardozo L, Chapple CR, Toozs-Hobson P et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU Int 2000; 85: 659-664.
121. Madersbacher H, Stohrer M, Richter R, Burgdorfer H, Hachen HJ, Murtz G. Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. Br J Urol 1995; 75: 452-456.
122. Donnellan CA, Fook L, McDonald P, Playfer JR. Oxybutynin and cognitive dysfunction. Br Med J 1997; 315: 1363-1364.
123. Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998; 46: 8-13.
124. Pietzko A, Dimpfel W, Schwantes U, Topfmeier P. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 1994; 47: 337-343.
125. Guarneri L, Robinson E, Testar R. A review of flavoxate: pharmacology and mechanism of action. Drugs Today 1994; 30: 91-98.
126. Chapple CR, Parkhouse H, Gardener C, Milroy EJG. Double blind, placebo controlled cross over study of flavoxate in the treatment of idiopathic detrusor instability. Br J Urol 1990; 66: 491-494.
127. Dahm TL, Ostri P, Kristensen JK et al. Flavoxate treatment of micturition disorders accompanying benign prostatic hypertrophy: a double blind, placebo controlled multi centre investigation. Urol Int 1995; 55: 205-208.
128. Stanton SL. A comparison of emepronium bromide and flavoxate hydrochloride in the treatment of urinary incontinence. J Urol 1973; 110: 529-832.
129. Milani R, Scalambrino S, Milia R et al. Double blind cross-over comparison of flavoxate and oxybutynin in women affected by urinary urge syndrome. Int Urogynecol J 1993; 4: 3-8.
130. Jeffcoate TNA, Francis WJA. Urgency incontinence. Am J Obstet Gynecol 1966; 94: 604-618.
131. Burgio KL, Locher JL, Goode PS et al. Behavioural versus drug treatment for urinary urge incontinence in older women. A randomized controlled trial. JAMA 1998; 280: 1995-2000.
132. Burgio KL, Locher JL, Goode PS. Combined behavioural and drug therapy for urge incontinence in older women. J Am Geriatr Soc 2000; 48: 370-374.
133. Donahue JL, Lowenthal DT. Nocturnal polyuria in the elderly person. Am J Med Sci 1997; 314: 232-238.
134. Hilton P, Stanton SL. The use of Desmopressin (DDAVP) in nocturnal frequency in the female. Br J Urol 1982; 54: 252-255.
135. Reynard JM, Cannon A, Yang Q, Abrams P. A novel therapy for nocturnal polyuria: a double-blind randomized trial of furosemide against placebo. Br J Urol 1998; 81: 215-218.
136. O'Donnell PD, Beck C, Walls RC. Serial incontinence assessment in elderly inpatient men. J Rehab Res Dev 1990; 27: 1-9.
137. Le Fanu J. The value of aspirin in controlling the symptoms of nocturnal polyuria. BJU Int 2001; 88: 126-127.
138. Asplund R, Sundberg B, Bergtsson P. Oral desmopressin for nocturnal polyuria in elderly subjects: a double blind, placebo-controlled randomized exploratory study. BJU Int 1999; 83: 591-595.
139. Ahlstrom K, Sandahl B, Sjoberg B, Ulmsten U, Stormby N, Lindskog M. Effect of combined treatment with phenylpropanolamine and estriol, compared with estriol treatment alone, in postmenopausal women with stress urinary incontinence. Gynecol Obstet Invest 1990; 30: 37-43.
140. Kinn AC, Lindskog M. Estrogens and phenylpropanolamine in combination for stress urinary incontinence in postmenopausal women. Urology 1988; 32: 273-280.
141. Obrink A, Bunne G. The effect of alpha-adrenergic stimulation in stress incontinence. Scand J Urol Nephrol 1978; 12: 205-208.
142. Lord SR, McClean D, Stathers G. Physiological factors associated with injurious falls in older people living in the community. Gerontology 1992; 38: 338-346.
143. Melton LJ, Chao YS, Lane J. Biochemical aspects of fractures. In Osteoporosis: etiology, diagnosis and management, 1st edn, eds Riggs BL, Melton LJ. New York: Raven Press, 1988; 111-131.
144. Gaerdsell P, Jonell O, Nilsson BE, Nillson JA. The predictive value of fracture, disease and falling tendency for fragility fractures in women. Calcif Tiss Inter 1989; 45: 327-330.
145. Cummings RG, Nevitt MC. A hypothesis: the causes of hip fractures. J Gerontol 1989; 44: 107-111.
146. Chapuy MC, Arlot ME, Duboeuf F, Brun J. Vitamin D3 and calcium to prevent hip fractures in elderly females. N Engl J Med 1992; 327: 1637-1642.
147. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in females and males 65 years of age and older. N Engl J Med 1997; 337: 670-676.
148. Costa E, Blau H, Felchnan D. Dihydroxyvitamin D3 receptors and hormonal responses in cloned human skeletal muscle cells. Endocrinology 1986; 119: 2214-2220.
149. Boland R. Role of vitamin D in skeletal muscle function. Endocrinol Rev 1986; 7: 434-448.
150. Birge SJ, Haddad JG. 25 hydroxycholecalciferol stimulation of muscle metabolism. J Clin Invest 1975; 56: 1100-1107.
151. Chapuy MC, Durr F, Chapuy P. Age related changes in PTH and 25 OH cholecalciferol levels. J Gerontol 1983; 38: 19-22.
152. Baczynski R, Massry SG, Magott M, el-Belbessi S, Kohan R, Brautbar N. Effect of parathyroid hormone on energy metabolism of skeletal muscle. Kidney Int 1985; 28: 722-727.
153. Hedman I, Grimby G, Tisell LE. Improvement of muscle strength after treatment for hyperparathyroidism. Acta Chir Scand 1984; 150: 521-524.
154. Schott GD, Wills MR. Muscle weakness in osteomalacia. Lancet 1976; 1: 626-629.
155. Boonen S, Lysens R, Verbeke G et al. Relationship between age associated endocrine deficiencies and muscle function in eldedy women: a cross sectional study. Age Ageing 1998; 27: 449-454.
156. Mowe M, Haug E, Bohmer T. Low serum calcidiol concentration in older adults and reduced muscular function. J Am Geriatr Soc 1999; 47: 220-226.
157. Bischoff HA, Stahelin HB, Urscheler N. Muscle strength in the elderly: its relation to vitamin D metabolites. Arch Phys Med Rehab 1999; 80: 54-58.
158. 3 and muscle strength in the elderly: a randomised controlled trial. J Clin Endo Metab 1991; 73: 1111-1117.
159. Geusens P, Vandevyver C, Vanhoof J, Cassiman JJ, Boonen S, Raus J. Quadriceps and grip strength are related to vitamin D receptor genotype in elderly nonobese women. J Bone Miner Res 1997; 12: 2082-2088.
160. Verhaar HJ, Samson MM, Jansen PA, de Vreede PL, Manten JW, Duursma SA. Muscle strength, functional mobility and vitamin D in older women. Aging (Milan) 2000; 12: 455-460.
161. Van Veldhuizen PJ, Taylor SA, Williamson S, Drees BM. Treatment of vitamin D deficiency in patients with metastatic prostatic cancer may improve bone pain and muscle strength. J Urol 2000; 163: 187-190.
162. Neveu I, Naveilhan P, Jehan F. Rat brain glial cells synthesise and respond to 1,25-dihydroxy-vitamin D3 by an increased production of nerve growth factor. In Vitamin D. A pluripotent steroid hormone, eds Norman A, Bouillon R, Thomasset M. Orlando, FL: 1994; 621-628.
163. Yanagihara R, Garruto RM, Gajdusek DC et al. Calcium and vitamin D metabolism in Guamanian Chamorros with amyotrophic lateral sclerosis and parkinsonism-dementia. Ann Neurol 1984; 15: 42-48.
164. Begerow B, Pfeifer M, Pospeschill M, Scholz M. Vitamin D impairs strength and body sway in patients with post menopausal osteoporosis and increases risk of falling. J Bone Miner Res 1997; 12: T468.
165. Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C. Effects of a short term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 2000; 15: 1113-1118.
166. Mets T. Calcium, vitamin D and hip fractures. Incidence of falls may have decreased. Br Med J 1994; 309: 193.
167. Sorensen OH, Lund B, Saltin B, Lund BJ. Myopathy in bone loss of ageing: improvement by treatment with 1 alpha hydroxycholecalciferol and calcium. Clin Sci 1979; 56: 157-161.
168. Gloth FMI, Smith CE, Hollis BW, Tobin JD. Functional improvement with vitamin D replenishment in a cohort of frail vitamin D deficient older people. J Am Geriatr Soc 1995; 43: 1269-1271.
169. Gloth FMI, Lindsay JM, Zelesnick LB, Greenough WBI. Can vitamin D deficiency produce an unusual pain syndrome? Arch Intern Med 1991; 151: 1662-1664.